Article

Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma.

Faculty of Dentistry, University of Toronto, 124 Edward St., Toronto, Canada, M5G 1G6.
Oncogene (Impact Factor: 8.56). 03/2001; 20(5):654-8. DOI: 10.1038/sj.onc.1204131
Source: PubMed

ABSTRACT Oral squamous cell carcinoma (OSCC) is associated with heavy smoking and drinking, but the molecular pathway of tumorigenesis is not understood. Inactivation of the p53 tumor suppressor gene is likely to play an important role since p53 mutation is frequently found. The p14ARF tumor suppressor gene is functionally linked to p53, because it is activated by oncogenes and causes p53-dependent growth arrest and apoptosis. The relationship between p14ARF and p53 inactivation has not been described for OSCC. We studied 25 cases of OSCC to determine if there is an inverse correlation between p53 mutation and p14ARF inactivation by homozygous deletion or mutation. p53 mutation was found in 16 of 25 cases (64%), including nine missense and seven truncating mutations. While all cases with missense mutations showed abnormal accumulation of p53 protein, there were also five carcinomas which showed increased p53 staining in the absence of mutation. p14ARF deletion or mutation was found in eight cases (32%), six of which also demonstrated p53 mutation. Our findings indicate that OSCC often involves loss of both p14ARF and p53 function and suggest that inactivation of these two tumor suppressor genes are not functionally equivalent during tumorigenesis.

0 Bookmarks
 · 
48 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since p14(ARF)and HPV16 E6/E7 oncoproteins are important regulators participating the p53/Rb pathways, genetic variations of p14(ARF) may modify tumor HPV16 status and survival of HPV16-positive SCCOP patients. We determined tumor HPV16 status and expression of p14/p53, and genotyped p14(ARF) rs3731217 and rs3088440 polymorphisms in 552 incident SCCOP patients. We found that patients having variant genotypes for each p14(ARF) polymorphism were approximately twice or three times as likely to have HPV16-positive tumors compared with patients with corresponding common homozygous genotype, and such an association was particularly pronounced in patients with variant genotypes of both polymorphisms. After definitive chemoradiotherapy, patients having p14(ARF) rs3731217 TG/GG variant genotypes had significantly better overall, disease-specific, and disease-free survival than those having TT genotype, respectively. Multivariable analysis found that patients with p14(ARF) rs3731217 TT genotype had an approximately 7, 11, and 3-fold increased risk for death overall, death due to SCCOP, and recurrence than those with TG/GG variant genotypes, respectively. Furthermore, such significantly prognostic effect was also found when survival analysis was limited to HPV16-positive patients. Additionally, potentially functional relevance of the two variants was characterized to explore the genotype-phenotype correlation. Our findings indicate p14(ARF) variants may predict tumor HPV16-positive SCCOP patients and survival.
    Carcinogenesis 10/2013; · 5.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Occurrence of genetic and epigenetic alterations affecting p14ARF and p16INK4A were investigated in tumour samples of 37 oral (OSCC) and 28 laryngeal squamous cell cancer (LSCC) patients, and compared to exfoliated buccal epithelial cells of 68 healthy controls. Presence of deletions and mutations/polymorphisms affecting exons were examined using sequencing. Methylation status of promoters was assessed by methylation-specific PCR. Chi-square and Fisher's exact tests were used to compare frequency of events. Exon deletions were found in four controls, one OSCC and 22 LSCC patients; the latter significantly differed from controls (p < 0.001). Only two mutations (T24610A and C24702A) were in p16 exon 1 of two OSCC patients. Polymorphisms G28575A (Ala140Thr), G31292C (C540G) and G28608A were found in both patient groups. The p14 promoter was unmethylated in 86.7 % of OSCC and in 85.7 % of LSCC patients; for the p16 promoter these rates were 69.0 % and 76.2 % for OSCC and LSCC patients, respectively. Combining the two patient groups, unmethylated promoter was significantly less frequent in case of both p14 and p16 (p = 0.043 and p = 0.001, respectively) compared to the control group. In summary, exon deletion may be important in LSCC, while promoter methylation was relatively frequent in both patient groups.
    Pathology & Oncology Research 04/2014; · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The majority of conventional leukoplakia remains constant and only a subset progress to high grade dysplasia or invasive carcinoma. A less recognized form known as proliferative verrucous leukoplakia (PVL) represents a unique progressive and elusive variant. Identifying patients with this form can only be achieved through the keen clinical observation of the temporal gross and histologic progression in individual patients to squamous cell carcinoma. The difficulty in the early diagnosis of PVL stems from the overlapping clinical and pathologic features with conventional multifocal leukoplakia with dysplasia. We present the current view on the clinicopathologic and biological characteristics of PVL and discuss their diagnosis, differential diagnosis and management. Head Neck, 2013.
    Head & Neck 09/2013; · 2.83 Impact Factor

Full-text (2 Sources)

Download
6 Downloads
Available from
May 19, 2014